Veeck, JürgenRopero, SantiagoSetién, FernandoGonzalez-Suarez, EvaOsorio, AnaBenitez, JavierHerman, James G.Esteller, Manel, 1968-2023-05-262023-05-262010-10-100732-183Xhttps://hdl.handle.net/2445/198525Recently, Fong et al reported the antitumor activity of the poly(adenosine diphosphate)-ribose polymerase (PARP) inhibitor olaparib (AZD2281; KU-0059436) in patients with BRCA1/BRCA2 germline mutated ovarian cancer. Female BRCA1 and BRCA2 mutation carriers have a significantly elevated lifetime risk of breast and ovarian cancer. BRCA1 and BRCA2 proteins play major roles in DNA double-strand break repair through homologous recombination, and inhibition of DNA single-strand break repair leads to the accumulation of double-strand breaks. These potentially lethal events in homologous recombination-deficient cells could be exploited for therapeutic purposes. The PARP-1 protein is essential for single-strand break repair, and inhibition of PARP leads to persistence of DNA lesions normally repaired by homologous recombination.1 p.application/pdfeng(c) American Society of Clinical Oncology, 2010Proteïnes supressores de tumorsADNMalalties de l'ovariGenèticaTumor suppressor proteinDNAOvary diseasesGeneticsinfo:eu-repo/semantics/article7002342023-05-26info:eu-repo/semantics/openAccess2067960520679605